Celgene $9 billion acquisition of Juno Therapeutics

22/1/2018

Public acquisition

Value:

$ 9 billion

Status:

Announced

Date:

22/1/2018

Overview:

Biotechnology company Celgene has acquired Juno Therapeutics in a $9 billion deal.
Celgene previously held 9.7% of Juno.
Juno develops cancer immunotherapy drugs.
JP Morgan Securities acted as financial adviser for Celgene and Morgan Stanley advised Juno.
The deal comes on the same day as Sanofi's $11.6 billion acquisition of Bioverativ.

Kurt Stumpo - Journalist

Jurisdiction:

United States

Deal type:

Public acquisition

Practice area:

M&A

Governing law:

United States

Industry sector:

Pharmaceuticals and life sciences

Firms:

Hogan Lovells

Party: Celgene (Acquirer)

Proskauer Rose

Party: Celgene (Acquirer)

Lawyers: Daniel Ganitsky, Michael Ellis, Robert Cantone

Skadden Arps Slate Meagher & Flom

Party: Juno Therapeutics (Target)

Sullivan & Cromwell

Party: Morgan Stanley (Financial adviser)

Lawyer: Matthew Hurd

Related deals